

### Daftar Pustaka

1. Unit Kerja Koordinasi Nefrologi Ikatan Dokter Anak Indonesia. *Konsensus tata laksana sindrom nefrotik idiopatik pada anak*. Edisi Kedua. Jakarta: Badan Penerbit Ikatan Dokter Anak Indonesia; 2012;2:2-19.
2. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR. Clinical practice guideline for screening and management. *Pediatrics*.2017;140:1-74.
3. Andersen RF, Thrane N, Noergaard K, Rytter L, Jespersen B, Rittig S. Early age at debut is a predictor of steroid-dependent and frequent relapsing nephrotic syndrome. *Pediatr Nephrol*.2010;25:1299–304.
4. Abdel-Hafez MA, Abou-El-Hana NM, Erfan AA, El-Gamasy M, Abdel-Nabi H. Predictive risk factors of steroid dependent nephrotic syndrome in children. *J Nephro pathol*.2017;6:180-6.
5. Ozlu SG, Demircin G, Tokmeci N, Yilmaz AC, Aydog O, Bulbul M, et al. Long-term prognosis of idiopathic nephrotic syndrome in children. *Ren Fail, Early Online*.2015:1-6.
6. Ishikura K, Yoshikawa N, Nakazato H, Sasaki S, Nakanishi K, Matsuyama T, et al. Morbidity in children with frequently relapsing nephrosis: 10-year follow-up of randomized controlled trial. *Pediatr Nephrol*.2015;30:459-68.
7. Bagga A, Mantan M. Nephrotic Syndrome in children. *Indian J Med Res*.2005;122:13-28.
8. Tamez-Perez HE, Quintanilla-Flores DL, Rodriguez-Gutierrez R, Gonzalez JG, Tamez-Pena AL. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. *World J Diabetes*.2015;6:1073-81.
9. Takeda A, Ohgushi H, Niimura F, Matsutani H. Long-term effects of immunosuppressants in steroid-dependent nephrotic syndrome. *Pediatr Nephrol*.1998;12:746-50.

10. Cammas B, Harambat J, Bertholet-Thomas A, Bouissou F, Morin D, Guignonis V, et al. Long-term effects of cyclophosphamide therapy in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. *Nephrol Dial Transplant*.2011;26:178-84.
11. Kyrieleis HA, Levchenko EN, Wetzels JF. Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome. *Am J Kidney Dis*.2007;49:592-7.
12. Fathallah-Shaykh SA. Proteinuria and progression of pediatric chronic kidney disease: lessons from recent clinical studies. *Pediatr Nephrol*.2017;32:743-51.
13. Ruggerenti P, Cravedi P, Chianca A, Caruso M, Remuzzi G. Achieving remission of proteinuria in childhood CKD. *Pediatr Nephrol*.2017;32:321-30.
14. Palmer BF. Proteinuria as a therapeutic target in patients with chronic kidney disease. *Am J Nephrol*.2007;27:287-93.
15. Jackevicius CA, Wong J, Aroustamian I, Gee M, Mody FV. Rates and predictors of ACE inhibitor discontinuation subsequent to elevated serum creatinine: a retrospective cohort study. *BMJ Open*.2014;4:e005181.
16. Hari P, Sahu J, Sinha A, Pandey RM, Bal CS, Bagga A. Effect of enalapril on glomerular filtration rate and proteinuria in children with chronic kidney disease: a randomized controlled trial. *Indian Pediatrics*.2013;50:923-8.
17. Sasinka MA, Podracka L, Boor A, Jurkovic I, Mitro A, Kovacs L. Enalapril treatment of proteinuria in normotensive children. *Bratisl Lek Listy*.1999;100:476-80.
18. Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, Santoro EP, et al. Losartan and enalapril are comparable in reducing proteinuria in children. *Kidney Int*. 2012;82:819-26.
19. Adedoyin OT, Ologe MO, Anigilaje EA, Adeniyi A. Effect of lisinopril on proteinuria in children with nephrotic syndrome in Ilorin, Nigeria. *Pediatr Nephrol*.2003;18:727-8.

20. Seeman T, Dusek J, Vondrak K, Flogelova H, Geier P, Janda J. Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney disease. *Am J Hypertens.*2004;17:415-20.
21. Trihono PP, Alatas H, Tambunan T, Sastroasmoro S. Kadar *transforming growth factor-β1* urin pada berbagai keadaan proteinuria. *Sari Pediatri.*2009;20:309-15.
22. Wasilewska AM, Zoch-Zwierz WM. Transforming growth factor-beta1 in nephrotic syndrome treated with cyclosporine and ACE inhibitors. *Pediatr Nephrol.* 2004;19:1349-53.
23. Luno J, Praga M, Vinuesa SG. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS). *Current Pharmaceutical Design.*2005;11:1291-1300.
24. Athavale A, Roberts DM. Management of proteinuria: blockade of the renin-angiotensin-aldosterone system. *Aust Prescr.*2020;43:121-5.
25. Cases A, Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. *Kidney Int.*2005;68:S87-93.
26. Krishnamurthy C, Rukmani J, Clarin D. Evaluation of serum lipid profile in children with nephrotic syndrome admitted in emergency ward of Government Tirunelveli Medical College and Hospital, India. *Int J Contemp pediatr.*2018;5:2244-8.

